Med Tech Earnings In Brief
This article was originally published in The Gray Sheet
Executive Summary
Duraheart progress: German clinical trials of Terumo's destination therapy left-ventricular assist system will conclude by mid-2005, with European CE mark anticipated in 2006, the Japanese company reports during a July 28 earnings call. So far, nine patients have been implanted with the device, which Terumo calls "the world's first LVAS with a magnetically suspended centrifugal pump." In the U.S., Ann Arbor, Mich.-based Terumo Heart, Inc. is handling R&D and regulatory activities....Anaconda swoops for AAA market: Terumo expects a CE mark for its abdominal aortic aneurysm endograft in 2005, the firm notes, adding that four patients have received the implant in U.S. trials. Terumo targets 2007 for a U.S. launch of the AAA endograft - acquired along with Centerpulse unit Vascutek in 2002...